Sign up Australia
Proactive Investors - Run By Investors For Investors

Admedus signs deal to market its heart tissue products in Spain and Portugal

The company recently raised $6 million to expand and progress its strategic projects.
a heart figure
With numerous catalysts on the horizon 2018 could be a watershed year for the company

Admedus Ltd (ASX:AHZ) has signed an exclusive distribution agreement with leading healthcare group, Cardiva, to market and supply its ADAPT® tissue products in Spain and Portugal.

Under the agreement, Cardiva will initially distribute Admedus’ flagship ADAPT® tissue product CardioCel®, a non-calcifying, non-toxic bio-scaffold used to treat congenital heart defect and disease.

Additional ADAPT® products, VascuCel® and CardioCel 3D®, will be added to the Cardiva distribution portfolio later in the year.

Cardiva is a leading company in the Spanish and Portuguese health system, providing physicians access to a wide range of innovative devices in the areas of interventional cardiology, cardiac surgery and pain management.

Admedus chief operating officer David St Denis said: “Through this partnership with Cardiva, Admedus is thrilled to offer our clinically superior ADAPT® products to patients in Spain and Portugal - one of the five largest markets in Europe.

“With first orders due this month, we anticipate demand in this region to grow steadily as more surgeons are introduced to the unique clinical and health benefits of our ADAPT® technology,”

READ: Admedus secures $6 million to expand medical technologies strategy

Earlier this month, Admedus secured commitments to raise about $6 million from institutional and sophisticated investors in a placement at 30 cents per share.

Funds raised will enable the company to expand and progress its strategic projects, including the acceleration of its product portfolio from development to commercialisation.

Admedus has already submitted multiple patent applications in the US as it targets entry into the lucrative TAVR (transcatheter aortic valve replacement) market, currently worth US$3.5 billion and expected to grow to US$5 billion by 2020.

READ: Admedus has healthy mix of reliable Infusion earnings and strong revenue growth from ADAPT

Admedus has also invited existing shareholders to participate in a share purchase plan (SPP).

This offers the opportunity for each shareholder to subscribe for up to $15,000 worth of new Admedus shares by Monday, 28 May 2018 at a price of 30 cents per share.

View full AHZ profile View Profile

Admedus Ltd Timeline

Related Articles

June 27 2018
Ridinilazole is a possible treatment for C. Difficile and Summit hopes to kick off a phase III trial in the first quarter of 2019
cancer cells in blood
July 17 2018
It’s been a tricky year for Redx, but it has come through it with a promising pipeline, cash in the bank and AstraZeneca’s former UK boss as its new chief executive
February 02 2018
A first partnership agreement was signed with a South Korean company towards the end of 2017

No investment advice

The information on this Site is of a general nature only. It does not take your specific needs or circumstances into consideration, so you should look at your own financial position, objectives and requirements and seek financial advice before making any financial decisions. You acknowledge and understand that neither the Company, its related bodies corporate, the information providers or their affiliates will advise you personally about the nature, potential value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter. You should read our FSG and any other relevant disclosure documents and if necessary seek persona advice prior to making any investment decision.

You understand and agree that no Content (as defined below) published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person.

You understand that in certain circumstances the Company, its related bodies corporate, the information providers or their affiliates may have received, or be entitled to receive, financial or other consideration in connection with promoting, and providing information about, certain entities on the Site and in communications otherwise provided to you.

You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate. From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

Before you act on any general advice we provide, please consider whether it is appropriate for your personal circumstances.

© Proactive Investors 2018

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use